
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7066882/publications.pdf Version: 2024-02-01



#	Article	lF	CITATIONS
1	UK guidelines on the management of variceal haemorrhage in cirrhotic patients. Gut, 2015, 64, 1680-1704.	6.1	518
2	Elevated Alanine Aminotransferase Predicts New-Onset Type 2 Diabetes Independently of Classical Risk Factors, Metabolic Syndrome, and C-Reactive Protein in the West of Scotland Coronary Prevention Study. Diabetes, 2004, 53, 2855-2860.	0.3	324
3	Outpatient management of patients with low-risk upper-gastrointestinal haemorrhage: multicentre validation and prospective evaluation. Lancet, The, 2009, 373, 42-47.	6.3	311
4	Comparison of risk scoring systems for patients presenting with upper gastrointestinal bleeding: international multicentre prospective study. BMJ, The, 2017, 356, i6432.	3.0	247
5	Randomized controlled trial of carvedilol versus variceal band ligation for the prevention of the first variceal bleed. Hepatology, 2009, 50, 825-833.	3.6	235
6	Effects of a high-dose 24-h infusion of tranexamic acid on death and thromboembolic events in patients with acute gastrointestinal bleeding (HALT-IT): an international randomised, double-blind, placebo-controlled trial. Lancet, The, 2020, 395, 1927-1936.	6.3	224
7	Endoscopic diagnosis and management of nonvariceal upper gastrointestinal hemorrhage (NVUGIH): European Society of Gastrointestinal Endoscopy (ESGE) Guideline – Update 2021. Endoscopy, 2021, 53, 300-332.	1.0	215
8	Restrictive versus liberal blood transfusion for acute upper gastrointestinal bleeding (TRIGGER): a pragmatic, open-label, cluster randomised feasibility trial. Lancet, The, 2015, 386, 137-144.	6.3	207
9	A randomized trial comparing transjugular intrahepatic portosystemic stent-shunt with variceal band ligation in the prevention of rebleeding from esophageal varices. Hepatology, 1997, 26, 1115-1122.	3.6	196
10	Transjugular intrahepatic portosystemic stent-shunt in the management of portal hypertension. Gut, 2020, 69, 1173-1192.	6.1	182
11	Primary prophylaxis of variceal hemorrhage: A randomized controlled trial comparing band ligation, propranolol, and isosorbide mononitrate. Gastroenterology, 2002, 123, 735-744.	0.6	171
12	Hepatic granulomas: a 10 year single centre experience. Journal of Clinical Pathology, 2003, 56, 850-853.	1.0	158
13	Management of acute upper gastrointestinal bleeding. BMJ: British Medical Journal, 2019, 364, I536.	2.4	137
14	Validation of a Machine Learning Model That Outperforms Clinical Risk Scoring Systems for Upper Gastrointestinal Bleeding. Gastroenterology, 2020, 158, 160-167.	0.6	133
15	Restrictive versus liberal blood transfusion for gastrointestinal bleeding: a systematic review and meta-analysis of randomised controlled trials. The Lancet Gastroenterology and Hepatology, 2017, 2, 354-360.	3.7	131
16	Multicentre comparison of the Glasgow Blatchford and Rockall scores in the prediction of clinical end-points after upper gastrointestinal haemorrhage. Alimentary Pharmacology and Therapeutics, 2011, 34, 470-475.	1.9	120
17	Hemospray Application in Nonvariceal Upper Gastrointestinal Bleeding. Journal of Clinical Gastroenterology, 2014, 48, e89-e92.	1.1	115
18	Effects of HRT on liver enzyme levels in women with type 2 diabetes: a randomized placebo-controlled trial. Clinical Endocrinology, 2006, 65, 40-44.	1.2	114

#	Article	IF	CITATIONS
19	Relationship between timing of endoscopy and mortality inÂpatients with peptic ulcer bleeding: a nationwide cohortÂstudy. Gastrointestinal Endoscopy, 2017, 85, 936-944.e3.	0.5	107
20	Toward a more complete understanding of the association between a hepatitis C sustained viral response and causeâ€specific outcomes. Hepatology, 2015, 62, 355-364.	3.6	102
21	Performance of New Thresholds of the Glasgow Blatchford Score in Managing Patients With Upper Gastrointestinal Bleeding. Clinical Gastroenterology and Hepatology, 2015, 13, 115-121.e2.	2.4	92
22	Ten years??? follow-up of 472 patients following transjugular intrahepatic portosystemic stent-shunt insertion at a single centre. European Journal of Gastroenterology and Hepatology, 2004, 16, 9-18.	0.8	90
23	The risk of hepatocellular carcinoma in cirrhotic patients with hepatitis C and sustained viral response: Role of the treatment regimen. Journal of Hepatology, 2018, 68, 646-654.	1.8	82
24	Haemodynamic parameters predicting variceal haemorrhage and survival in alcoholic cirrhosis. QJM - Monthly Journal of the Association of Physicians, 1998, 91, 19-25.	0.2	80
25	ABC score: a new risk score that accurately predicts mortality in acute upper and lower gastrointestinal bleeding: an international multicentre study. Gut, 2021, 70, 707-716.	6.1	77
26	Hepatitis E virus in patients with decompensated chronic liver disease: a prospective <scp>UK</scp> /French study. Alimentary Pharmacology and Therapeutics, 2015, 42, 574-581.	1.9	76
27	Faecal calprotectin in the assessment of Crohn's disease activity. QJM - Monthly Journal of the Association of Physicians, 2005, 98, 435-441.	0.2	73
28	A comparison between gastric and oesophageal variceal haemorrhage treated with transjugular intrahepatic portosystemic stent shunt (TIPSS). Alimentary Pharmacology and Therapeutics, 1997, 11, 171-176.	1.9	72
29	Haemodynamic effects of acute and chronic administration of low-dose carvedilol, a vasodilating β-blocker, in patients with cirrhosis and portal hypertension. Alimentary Pharmacology and Therapeutics, 2002, 16, 373-380.	1.9	72
30	Acute and chronic haemodynamic and renal effects of carvedilol in patients with cirrhosis. Journal of Hepatology, 1999, 30, 479-484.	1.8	66
31	The use of hemospray in portal hypertensive bleeding; a case series. Journal of Hepatology, 2014, 60, 457-460.	1.8	66
32	Longterm follow up of transjugular intrahepatic portosystemic stent shunt (TIPSS) for the treatment of portal hypertension: results in 130 patients Gut, 1996, 39, 479-485.	6.1	64
33	Carvedilol reduces the risk of decompensation and mortality in patients with compensated cirrhosis in a competing-risk meta-analysis. Journal of Hepatology, 2022, 77, 1014-1025.	1.8	64
34	Costs and quality of life associated with acute upper gastrointestinal bleeding in the UK: cohort analysis of patients in a cluster randomised trial. BMJ Open, 2015, 5, e007230-e007230.	0.8	57
35	Nodular regenerative hyperplasia of the liver: survival and associated features in a UK case series. European Journal of Gastroenterology and Hepatology, 2010, 22, 1001-1005.	0.8	56
36	Spontaneous bacterial peritonitis-diagnosis, treatment and prevention. Alimentary Pharmacology and Therapeutics, 2001, 15, 1851-1859.	1.9	55

#	Article	IF	CITATIONS
37	Update on risk scoring systems for patients with upper gastrointestinal haemorrhage. World Journal of Gastroenterology, 2012, 18, 2739.	1.4	54
38	Multicentre randomised controlled study comparing carvedilol with variceal band ligation in the prevention of variceal rebleeding. Journal of Hepatology, 2014, 61, 1014-1019.	1.8	54
39	Transjugular intrahepatic portosystemic shunt as a treatment for protein-losing enteropathy caused by portal hypertension. Gastroenterology, 1996, 111, 1679-1682.	0.6	52
40	Abnormal liver function tests following bone marrow transplantation. European Journal of Gastroenterology and Hepatology, 2004, 16, 157-162.	0.8	52
41	Factors associated with spontaneous clearance of chronic hepatitis C virus infection. Journal of Hepatology, 2016, 65, 266-272.	1.8	52
42	Randomised clinical trial: standard of care versus earlyâ€transjugular intrahepatic portoâ€systemic shunt (TIPSS) in patients with cirrhosis and oesophageal variceal bleeding. Alimentary Pharmacology and Therapeutics, 2020, 52, 98-106.	1.9	52
43	Quantifying the fraction of cirrhosis attributable to alcohol among chronic hepatitis C virus patients: Implications for treatment cost-effectiveness. Hepatology, 2013, 57, 451-460.	3.6	51
44	Mortality in hepatitis C patients who achieve a sustained viral response compared to the general population. Journal of Hepatology, 2017, 66, 19-27.	1.8	44
45	Portal hypertension and variceal haemorrhage. Lancet, The, 1997, 350, 1235-1239.	6.3	43
46	Hepatitis C reinfection following treatment induced viral clearance among people who have injected drugs. Drug and Alcohol Dependence, 2016, 165, 53-60.	1.6	43
47	Endoscopic ultrasound-guided elastography in the nodal staging of oesophageal cancer. World Journal of Gastroenterology, 2012, 18, 889.	1.4	42
48	The transjugular intrahepatic portosystemic shunt (TIPS). Clinical Radiology, 2009, 64, 664-674.	0.5	41
49	Upper gastrointestinal bleeding in Scotland 2000-2010: Improved outcomes but a significant weekend effect. World Journal of Gastroenterology, 2015, 21, 10890.	1.4	40
50	Long-term follow-up of endoscopic Histoacryl glue injection for the management of gastric variceal bleeding. QJM - Monthly Journal of the Association of Physicians, 2011, 104, 41-47.	0.2	39
51	Neutrophil activation in chronic liver disease. European Journal of Gastroenterology and Hepatology, 1996, 8, 135-138.	0.8	37
52	Carvedilol is associated with improved survival in patients with cirrhosis: a longâ€ŧerm followâ€up study. Alimentary Pharmacology and Therapeutics, 2021, 53, 531-539.	1.9	35
53	Value of predictive genetic testing in management of hereditary nonâ€polyposis colorectal cancer (HNPCC). Medical Journal of Australia, 2000, 172, 313-316.	0.8	34
54	Update on gastric varices. World Journal of Gastrointestinal Endoscopy, 2014, 6, 168.	0.4	32

4

#	Article	IF	CITATIONS
55	Clinical response after transjugular intrahepatic portosystemic stent shunt insertion for refractory ascites in cirrhosis. Alimentary Pharmacology and Therapeutics, 1996, 10, 801-806.	1.9	31
56	Systemic, portal and renal effects of terlipressin in patients with cirrhotic ascites: Pilot study. Journal of Gastroenterology and Hepatology (Australia), 2004, 19, 73-77.	1.4	31
57	Use of hemostatic powder (Hemospray) in the management of refractory gastric variceal hemorrhage. Endoscopy, 2013, 45, E86-E87.	1.0	31
58	British Society of Gastroenterology (BSG)-led multisociety consensus care bundle for the early clinical management of acute upper gastrointestinal bleeding. Frontline Gastroenterology, 2020, 11, 311-323.	0.9	30
59	Natriuretic effect of an adenosine-1 receptor antagonist in cirrhotic patients with ascites. Gastroenterology, 1998, 115, 406-411.	0.6	28
60	Acute effects of transjugular intrahepatic portosystemic stent-shunt (TIPSS) procedure on renal blood flow and cardiopulmonary hemodynamics in cirrhosis. American Journal of Gastroenterology, 1998, 93, 2463-2468.	0.2	27
61	Ranking predictors of a sustained viral response for patients with chronic hepatitis C treated with pegylated interferon and ribavirin in Scotland. European Journal of Gastroenterology and Hepatology, 2012, 24, 646-655.	0.8	27
62	Restrictive vs Liberal Blood Transfusion for Acute Upper Gastrointestinal Bleeding: Rationale and Protocol for a Cluster Randomized Feasibility Trial. Transfusion Medicine Reviews, 2013, 27, 146-153.	0.9	26
63	The management of alcoholic hepatitis: a prospective comparison of scoring systems. Alimentary Pharmacology and Therapeutics, 2013, 38, 603-610.	1.9	26
64	Hereditary diffuse gastric cancer associated with E-cadherin mutation: penetrance after all. European Journal of Gastroenterology and Hepatology, 2008, 20, 1205-1213.	0.8	24
65	Acute Upper Gastrointestinal Bleeding in the Elderly. Drugs and Aging, 2012, 29, 933-940.	1.3	24
66	Clinical utility of pre-endoscopy risk scores in upper gastrointestinal bleeding. Expert Review of Gastroenterology and Hepatology, 2019, 13, 1161-1167.	1.4	23
67	MAP(ASH): A new scoring system for the prediction of intervention and mortality in upper gastrointestinal bleeding. Journal of Gastroenterology and Hepatology (Australia), 2020, 35, 82-89.	1.4	23
68	Assessment of liver histology in patients with hepatitis C and normal transaminase levels. European Journal of Gastroenterology and Hepatology, 1996, 8, 869-72.	0.8	23
69	Previous Use of Antithrombotic Agents Reduces Mortality and Length of Hospital Stay in Patients With High-risk Upper Gastrointestinal Bleeding. Clinical Gastroenterology and Hepatology, 2019, 17, 440-447.e2.	2.4	22
70	Transjugular intrahepatic portosystemic stent-shunt (TIPSS) insertion as a prelude to orthotopic liver transplantation in patients with severe portal hypertension. European Journal of Gastroenterology and Hepatology, 1996, 8, 1145-1149.	0.8	21
71	Is the Glasgow Blatchford score useful in the risk assessment of patients presenting with variceal haemorrhage?. European Journal of Gastroenterology and Hepatology, 2014, 26, 432-437.	0.8	21
72	Attendance at specialist hepatitis clinics and initiation of antiviral treatment among persons chronically infected with hepatitis <scp>C</scp> : examining the early impact of <scp>S</scp> cotland's <scp>H</scp> epatitis <scp>C A</scp> ction <scp>P</scp> lan. Journal of Viral Hepatitis, 2014, 21, 366-376.	1.0	21

#	Article	IF	CITATIONS
73	Endoscopic mucosal resection for gastroesophageal cancer in a U.K. population. Long-term follow-up of a consecutive series. Surgical Endoscopy and Other Interventional Techniques, 2011, 25, 543-548.	1.3	19
74	Severity and Outcomes of Upper Gastrointestinal Bleeding With Bloody Vs. Coffee-Grounds Hematemesis. American Journal of Gastroenterology, 2018, 113, 358-366.	0.2	19
75	Is portal hypertension associated with protein-losing enteropathy?. Journal of Gastroenterology and Hepatology (Australia), 2005, 20, 103-107.	1.4	18
76	Shunt insufficiency after transjugular intrahepatic portosystemic stent-shunt: the whens, whys, hows and what should we do about it?. Clinical Radiology, 1997, 52, 329-331.	0.5	17
77	Randomised controlled trial of long term portographic follow up versus variceal band ligation following transjugular intrahepatic portosystemic stent shunt for preventing oesophageal variceal rebleeding. Gut, 2004, 53, 431-437.	6.1	17
78	Outpatient management of low-risk patients with upper gastrointestinal bleeding. European Journal of Gastroenterology and Hepatology, 2015, 27, 512-515.	0.8	17
79	The Shock Index is not accurate at predicting outcomes in patients with upper gastrointestinal bleeding. Alimentary Pharmacology and Therapeutics, 2020, 51, 253-260.	1.9	17
80	Current management and novel therapeutic strategies for refractory ascites and hepatorenal syndrome. QJM - Monthly Journal of the Association of Physicians, 2001, 94, 293-300.	0.2	16
81	E-cadherin mutation-associated diffuse gastric adenocarcinoma: penetrance and non-penetrance. European Journal of Gastroenterology and Hepatology, 2005, 17, 1425-1428.	0.8	16
82	Bedside leucocyte esterase reagent strips with spectrophotometric analysis to rapidly exclude spontaneous bacterial peritonitis: a pilot study. European Journal of Gastroenterology and Hepatology, 2007, 19, 289-295.	0.8	16
83	Review article: update on the role of transjugular intrahepatic portosystemic stent-shunt (TIPSS) in the management of complications of portal hypertension. Alimentary Pharmacology and Therapeutics, 1997, 11, 261-272.	1.9	15
84	Endotherapy of Peptic Ulcer Bleeding. Gastrointestinal Endoscopy Clinics of North America, 2018, 28, 277-289.	0.6	15
85	Evidence of continued injecting drug use after attaining sustained treatment-induced clearance of the hepatitis C virus: Implications for reinfection. Drug and Alcohol Dependence, 2015, 154, 125-131.	1.6	14
86	Impact of previous hepatitis B infection on the clinical outcomes from chronic hepatitis C? A populationâ€level analysis. Journal of Viral Hepatitis, 2018, 25, 930-938.	1.0	14
87	Relationship of time to presentation after onset of upper GI bleeding with patient characteristics and outcomes: aAprospective study. Gastrointestinal Endoscopy, 2017, 86, 1028-1037.	0.5	13
88	The use of selective serotonin receptor inhibitors (<scp>SSRI</scp> s) is not associated with increased risk of endoscopyâ€refractory bleeding, rebleeding or mortality in peptic ulcer bleeding. Alimentary Pharmacology and Therapeutics, 2017, 46, 355-363.	1.9	11
89	Transjugular Intrahepatic Portosystemic Stent Shunt Placement in a Patient with Cystic Fibrosis Complicated by Portal Hypertension. Clinical Radiology, 2000, 55, 236-237.	0.5	9
90	The natural history of parallel transjugular intrahepatic portosystemic stent shunts using uncovered stent: the role of host-related factors. Liver International, 2006, 26, 572-578.	1.9	9

#	Article	IF	CITATIONS
91	Nodular regenerative hyperplasia related portal hypertension in a patient with hypogammaglobulinaemia. World Journal of Gastroenterology, 2013, 19, 3502.	1.4	9
92	International prospective observational study of upper gastrointestinal haemorrhage: Does weekend admission affect outcome?. United European Gastroenterology Journal, 2017, 5, 1082-1089.	1.6	9
93	Imatinib and liver toxicity. BMJ Case Reports, 2018, 11, e226740.	0.2	9
94	Acute effect of propranolol and isosorbide-5-mononitrate administration on renal blood flow in cirrhotic patients. Gut, 1998, 42, 283-287.	6.1	8
95	A pharmacoscintigraphic study of three time-delayed capsule formulations in healthy male volunteers. Journal of Pharmaceutical Sciences, 2009, 98, 4251-4263.	1.6	8
96	Effect of Hepatocellular Carcinoma Surveillance Programmes on Overall Survival in a Mixed Cirrhotic UK Population: A Prospective, Longitudinal Cohort Study. Journal of Clinical Medicine, 2021, 10, 2770.	1.0	8
97	Coeliac disease presenting as variceal haemorrhage. Gut, 2003, 52, 758-758.	6.1	8
98	Carvedilol versus endoscopic band ligation for secondary prophylaxis of variceal bleeding—Longâ€ŧerm followâ€up of a randomised control trial. Alimentary Pharmacology and Therapeutics, 2022, , .	1.9	8
99	Efficacy of balloon angioplasty, restenting, and parallel shunt insertion for shunt insufficiency after transjugular intrahepatic portosystemic stent-shunt (TIPSS). Minimally Invasive Therapy and Allied Technologies, 1998, 7, 287-293.	0.6	7
100	Primary Hyperparathyroidsm, Amyloid and Multiple Myeloma: An Unusual Association. Scottish Medical Journal, 2005, 50, 32-34.	0.7	7
101	Raising the threshold for hospital admission and endoscopy in upper gastrointestinal bleeding during the COVID-19 pandemic. Endoscopy, 2020, 52, 930-931.	1.0	7
102	Comparison between theophylline and spironolactone in the management of cirrhotic ascites: a randomized controlled study. Alimentary Pharmacology and Therapeutics, 1998, 12, 389-393.	1.9	6
103	Bleeding gastric varices and antiphospholipid syndrome. Nature Reviews Gastroenterology & Hepatology, 2005, 2, 156-159.	1.7	6
104	Risk assessment scores for patients with upper gastrointestinal bleeding and their use in clinical practice. Hospital Practice (1995), 2015, 43, 290-298.	0.5	6
105	Uptake of endoscopic screening for gastroesophageal varices and factors associated with variceal bleeding in patients with chronic hepatitis C infection and compensated cirrhosis, 2005â€2016: a national database linkage study. Alimentary Pharmacology and Therapeutics, 2019, 50, 425-434.	1.9	6
106	Upper gastrointestinal bleeding in Scotland 2000â€⊋015: trends in demographics, aetiology and outcomes. Alimentary Pharmacology and Therapeutics, 2021, 53, 383-389.	1.9	6
107	Carvedilol?A new nonselective beta blocker. Hepatology, 2000, 31, 809-811.	3.6	5
108	The biochemical and clinical penetrance of individuals diagnosed with genetic haemochromatosis by predictive genetic testing. European Journal of Gastroenterology and Hepatology, 2008, 20, 379-383.	0.8	5

#	Article	IF	CITATIONS
109	Impact of EUS-FNA in the Management of Patients with Oesophageal Cancer. Scottish Medical Journal, 2009, 54, 30-33.	0.7	5
110	Prevalence of Genetic Haemochromatosis and Iron Overload in Patients Attending Rheumatology and Joint Replacement Clinics. Scottish Medical Journal, 2010, 55, 14-16.	0.7	5
111	The International Bleeding Risk Score: A New Risk Score that can Accurately Predict Mortality in Patients with Upper GI-Bleeding. Gastroenterology, 2017, 152, S149-S150.	0.6	5
112	Optimal timing of endoscopy in patients with acute upper gastrointestinal bleeding. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2019, 42-43, 101618.	1.0	5
113	Oesophageal Ulceration Secondary to Potassium Tablets. Scottish Medical Journal, 1994, 39, 118-119.	0.7	4
114	Regional Survey on the Management of Oesophageal Variceal Haemorrhage. Scottish Medical Journal, 1995, 40, 149-150.	0.7	4
115	Haemochromatosis: Where are all the Patients?. Scottish Medical Journal, 2001, 46, 99-100.	0.7	4
116	OC-003â€Multicentre Randomised Controlled Study Comparing Carvedilol with Endoscopic Band Ligation in the Prevention of Variceal Rebleeding. Gut, 2013, 62, A1.3-A2.	6.1	4
117	The efficacy and safety of treating hepatitis C in patients with a diagnosis of schizophrenia. Journal of Viral Hepatitis, 2014, 21, e48-51.	1.0	4
118	Medical care setting is associated with survival in acute upper gastro-intestinal bleeding: A cohort study. Digestive and Liver Disease, 2020, 52, 561-565.	0.4	4
119	The Value of Quantitative Faecal Immunochemical Testing as a Prioritisation Tool for the Endoscopic Investigation of Patients With Iron Deficiency. Frontiers in Medicine, 2021, 8, 700753.	1.2	4
120	Cerebral near infrared spectroscopy for the measurement of indocyanine green elimination in cirrhosis. Alimentary Pharmacology and Therapeutics, 2000, 14, 923-928.	1.9	3
121	Editorial: optimal dose of carvedilol in portal hypertension…nearly there. Alimentary Pharmacology and Therapeutics, 2018, 47, 1328-1329.	1.9	3
122	Faecal occult blood test screening for colorectal cancer ―what are we waiting for?. Australian and New Zealand Journal of Medicine, 1999, 29, 545-551.	0.5	2
123	The Changing Face of Hepatitis B in Greater Glasgow: epidemiological trends 1993–2007. Scottish Medical Journal, 2010, 55, 4-7.	0.7	2
124	Analyses of Bloody vs. Coffee-Grounds Hematemesis. American Journal of Gastroenterology, 2018, 113, 1253-1254.	0.2	2
125	OTU-09â€Use of early-TIPSS in patients with oesophageal variceal bleeding, a UK dual-centre randomised control trial. , 2019, , .		2
126	Unusual case of adult familial Menetrier disease in siblings. BMJ Case Reports, 2019, 12, e231175.	0.2	2

#	Article	IF	CITATIONS
127	Mediastinal node staging by positron emission tomography-computed tomography and selective endoscopic ultrasound with fine needle aspiration for patients with upper gastrointestinal cancer: Results from a regional centre. World Journal of Gastrointestinal Endoscopy, 2018, 10, 37-44.	0.4	2
128	The association between deprivation and the incidence and survival of patients with hepatocellular carcinoma in the West of Scotland. Expert Review of Gastroenterology and Hepatology, 2021, 15, 1427-1433.	1.4	2
129	Pathophysiology and management of portal hypertension. 2: Cirrhotic ascites. British Journal of Hospital Medicine, 1997, 58, 74-8.	0.0	2
130	Underdiagnosis of hereditary haemochromatosis: reflects lack of clinical not biochemical penetrance. Gut, 2003, 52, 455-455.	6.1	1
131	OC-022â€Multicentre comparison of the Glasgow Blatchford and Rockall scores in the prediction of clinical endpoints in upper gastrointestinal haemorrhage. Gut, 2010, 59, A9.3-A10.	6.1	1
132	Upper gastrointestinal bleeding: what's the score?. Scottish Medical Journal, 2011, 56, 167-169.	0.7	1
133	Corticosteroids for severe alcoholic hepatitis: what constitutes response?. Gut, 2011, 60, A232-A233.	6.1	1
134	Is the Glasgow Blatchford Score useful in the risk assessment of patients presenting with variceal haemorrhage?. Gut, 2011, 60, A45-A45.	6.1	1
135	Variceal rebleeding: use of drug therapy and endoscopic band ligation. Expert Review of Gastroenterology and Hepatology, 2014, 8, 179-183.	1.4	1
136	Editorial: proton pump inhibitors in cirrhosis. Alimentary Pharmacology and Therapeutics, 2015, 41, 592-592.	1.9	1
137	Outcomes with Bloody vs. Coffee-Grounds Hematemesis. American Journal of Gastroenterology, 2018, 113, 1727-1728.	0.2	1
138	Mo1188 - Rebleeding in Peptic Ulcer Bleeding — a Nationwide Cohort Study of 19,537 Patients. Gastroenterology, 2018, 154, S-701.	0.6	1
139	Editorial: acute gastrointestinal bleeding – proposed new study outcomes. Alimentary Pharmacology and Therapeutics, 2021, 54, 715-716.	1.9	1
140	MURAL: An Unsupervised Random Forest-Based Embedding for Electronic Health Record Data. , 2021, , .		1
141	Editorial: the impact of red blood cell transfusion on inpatient mortality in upper gastrointestinal bleeding. Alimentary Pharmacology and Therapeutics, 2022, 56, 336-337.	1.9	1
142	Update on the Management of Variceal Bleeding. Scottish Medical Journal, 2005, 50, 5-10.	0.7	0
143	Minimal deviation Barrett's adenocarcinoma: a diagnostic challenge. Diagnostic Histopathology, 2011, 17, 238-242.	0.2	0
144	PTU-180â€What is the role of EUS in nodal staging of oesophageal cancer in the era of PET-CT?. Gut, 2012, 61, A258.2-A258.	6.1	0

#	Article	IF	CITATIONS
145	Authors' reply to Dib. BMJ: British Medical Journal, 2017, 357, j3023.	2.4	Ο
146	Endoscopic therapy for upper gastrointestinal bleeding: less is more?. Frontline Gastroenterology, 2018, 9, 208.2-209.	0.9	0
147	Mo1189 - External Validation of the International Bleeding Risk Score: An International Multicentre Study. Gastroenterology, 2018, 154, S-701.	0.6	0
148	Letter: improve survival! Place early preâ€emptive TIPSS in highâ€risk variceal bleeders—Authors' reply. Alimentary Pharmacology and Therapeutics, 2020, 52, 929-930.	1.9	0
149	Letter: the Shock Index and predicting outcomes in patients with upper gastrointestinal bleeding. Author's reply. Alimentary Pharmacology and Therapeutics, 2020, 51, 312-313.	1.9	0
150	Twitter debate: controversies in management of upper gastrointestinal bleeding. Frontline Gastroenterology, 2021, 12, 437-439.	0.9	0
151	Increasing the low-risk threshold for patients with upper gastrointestinal bleeding during the COVID-19 pandemic: a prospective, multicentre feasibility study. Frontline Gastroenterology, 0, , flgastro-2021-101851.	0.9	0
152	Pathophysiology and management of portal hypertension. 1: Variceal haemorrhage. British Journal of Hospital Medicine, 1997, 58, 39-43.	0.0	0
153	Letter: enhancing training opportunities for upper GI bleeding in Sheffield ―a UK transferable model? Authors' reply. Alimentary Pharmacology and Therapeutics, 2021, 53, 1243-1243.	1.9	Ο